4D Molecular Therapeutics (FDMT) Stock
4D Molecular Therapeutics (FDMT) has a Tenet Score of 52 of 100 against 439 Healthcare peers, as of Nov 17, 2026.
Key stats
- Market cap
- $789.0M
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 6.96 – 16.93
- low → high
- Tenet Score
- 52/100
- Mixed · 439 Healthcare peers
Industry: Drugs · see every company filed here →
4D Molecular Therapeutics Inc scores 52/100. Mixed. Strongest on value and financial health, quality is the soft spot versus 439 Healthcare peers.
Tenet Score · vs sector
n=439Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Quality Compounder
- ~ Drawdown Context
- ✕ Reversal Evidence
- ✕ Not-a-Value-Trap Gate
13F flows & insider trades land here.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, car…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 13, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Corvus Pharmaceuticals IncCRVS | 53 | $897.5M |
| MeiraGTx Holdings plcMGTX | 63 | $897.2M |
| Pharming Group N.V.PHAR | 41 | $884.1M |
| Immatics N.VIMTX | 43 | $856.7M |
| Syndax Pharmaceuticals IncSNDX | 49 | $843.9M |
| Annexon IncANNX | 35 | $805.6M |
| Agility Robotics Inc.CCXI | 54 | $803.5M |
| Monte Rosa Therapeutics IncGLUE | 65 | $800.7M |
| Lexicon Pharmaceuticals IncLXRX | 51 | $797.0M |
| Collegium Pharmaceutical, IncCOLL | 61 | $786.8M |
Common questions
What sector and industry is 4D Molecular Therapeutics in?
4D Molecular Therapeutics is in the Healthcare sector and the Drugs industry.
What is 4D Molecular Therapeutics' Tenet Score?
4D Molecular Therapeutics' Tenet Score is 52 out of 100, ranked against 439 Healthcare peers as of Nov 17, 2026.




